![](https://www.molecular-medicine-israel.co.il/wp-content/uploads/2017/11/immunotherapy-300x129.jpg)
Engagement of MHC class I by the inhibitory receptor LILRB1 suppresses macrophages and is a target of cancer immunotherapy
Exciting progress in the field of cancer immunotherapy has renewed the urgency of the need for basic studies of immunoregulation in both adaptive cell lineages